Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Sangamo Therapeutics (NASDAQ: SGMO) announced after the bell on Thursday that it signed a partnership with Biogen (NASDAQ: BIIB) to develop a number of gene-editing treatments. The scope of the agreement would focus on neurological and neuromuscular conditions, with an initial focus on treating Alzheimer's and Parkinson's diseases.